A study of the allosteric inhibition of HCV RNA-dependent RNA polymerase and implementing virtual screening for the selection of promising dual-site inhibitors with low resistance potential

References

• Hepatitis C. Fact sheet No. 164. World Health Organization [Internet]. Available from: http://www.who.int/mediacentre/factsheets/fs164/en/ [last accessed Apr 2014].
   Google Scholar
• Kiyosawa K, Sodeyama T, Tanaka E, et al. Interrelationship of blood transfusion, non-A, non-B hepatitis and hepatocellular carcinoma: analysis by detection of antibody to hepatitis C virus. Hepatology 1990;12:671–5.
   PubMed Web of Science ®Google Scholar
• Tong MJ, el-Farra NS, Reikes AR, Co RL. Clinical outcomes after transfusion-associated hepatitis C. N Engl J Med 1995;332:1463–6.
   PubMed Web of Science ®Google Scholar
• Nakano T, Lau GM, Sugiyama M, Mizokami M. An updated analysis of hepatitis C virus genotypes and subtypes based on the complete coding region. Liver Int 2012;32:339–45.
   PubMed Web of Science ®Google Scholar
• Penin F, Dubuisson J, Rey FA, et al. Structural biology of hepatitis C virus. Hepatology 2004;39:5–19.
   PubMed Web of Science ®Google Scholar
• Behrens SE, Tomei L, De Francesco R. Identification and properties of the RNA-dependent RNA polymerase of hepatitis C virus. EMBO J 1996;15:12–22.
   PubMed Web of Science ®Google Scholar
• Deore RR, Chern JW. NS5B RNA dependent RNA polymerase inhibitors: the promising approach to treat hepatitis C virus infections. Curr Med Chem 2010;17:3806–26.
   PubMed Web of Science ®Google Scholar
• Kwo PY, Vinayek R. The therapeutic approaches for hepatitis C virus: protease inhibitors and polymerase inhibitors. Gut Liver 2011;5:406–17.
   PubMed Web of Science ®Google Scholar
• Oberg B. Rational design of polymerase inhibitors as antiviral drugs. Antiviral Res 2006;71:90–5.
   PubMed Web of Science ®Google Scholar
• Kitchen DB, Decornez H, Furr JR, Bajorath J. Docking and scoring in virtual screening for drug discovery: methods and applications. Nat Rev Drug Discov 2004;3:935–49.
   PubMed Web of Science ®Google Scholar
• Kaserer T, Beck KR, Akram M, et al. Pharmacophore models and pharmacophore-based virtual screening: concepts and applications exemplified on hydroxysteroid dehydrogenases. Molecules 2015;20:22799–832.
   PubMed Web of Science ®Google Scholar
• Begam BF, Kumar JS. Computer assisted QSAR/QSPR approaches – a review. Indian J Sci Technol 2016;9.
   Google Scholar
• Roy K, Kar S, Das RN. Understanding the basics of QSAR for applications in pharmaceutical sciences and risk assessment. San Diego (CA): Elsevier Science; 2015.
   Google Scholar
• Lin YT, Huang KJ, Tseng CK, et al. Efficient in silico assay of inhibitors of hepatitis C Virus RNA-dependent RNA polymerase by structure-based virtual screening and in vitro evaluation. Assay Drug Dev Technol 2011;9:290–8.
   PubMed Web of Science ®Google Scholar
• Yan S, Appleby T, Larson G, et al. Structure-based design of a novel thiazolone scaffold as HCV NS5B polymerase allosteric inhibitors. Bioorg Med Chem Lett 2006;16:5888–91.
   PubMed Web of Science ®Google Scholar
• Mysinger MM, Carchia M, Irwin JJ, Shoichet BK. Directory of useful decoys, enhanced (DUD-E): better ligands and decoys for better benchmarking. J Med Chem 2012;55:6582–94.
   PubMed Web of Science ®Google Scholar
• Elhefnawi M, ElGamacy M, Fares M. Multiple virtual screening approaches for finding new hepatitis C virus RNA-dependent RNA polymerase inhibitors: structure-based screens and molecular dynamics for the pursue of new poly pharmacological inhibitors. BMC Bioinformatics 2012;13:S5.
   PubMed Web of Science ®Google Scholar
• Koes DR, Camacho CJ. ZINCPharmer: pharmacophore search of the ZINC database. Nucleic Acids Res 2012;40:W409–14.
   PubMed Web of Science ®Google Scholar
• Mahmoud AH, Abou El Ella DA, Ismail MA, Abouzid KA. A highly selective structure-based virtual screening model of Palm I allosteric inhibitors of HCV Ns5b polymerase enzyme and its application in the discovery and optimization of new analogs. Eur J Med Chem 2012;57:468–82.
   PubMed Web of Science ®Google Scholar
• Beaulieu PL, Coulombe R, Duan J, et al. Structure-based design of novel HCV NS5B thumb pocket 2 allosteric inhibitors with submicromolar gt1 replicon potency: discovery of a quinazolinone chemotype. Bioorg Med Chem Lett 2013;23:4132–40.
   PubMed Web of Science ®Google Scholar
• Anilkumar GN, Selyutin O, Rosenblum SB, et al. Novel HCV NS5B polymerase inhibitors: discovery of indole C2 acyl sulfonamides. Bioorg Med Chem Lett 2012;22:713–17.
   PubMed Web of Science ®Google Scholar
• Gopalsamy A, Chopra R, Lim K, et al. Discovery of proline sulfonamides as potent and selective hepatitis C virus NS5b polymerase inhibitors. Evidence for a new NS5b polymerase binding site. J Med Chem 2006;49:3052–5.
   PubMed Web of Science ®Google Scholar
• Biswal BK, Wang M, Cherney MM, et al. Non-nucleoside inhibitors binding to hepatitis C virus NS5B polymerase reveal a novel mechanism of inhibition. J Mol Biol 2006;361:33–45.
   PubMed Web of Science ®Google Scholar
• Chan L, Das SK, Reddy TJ, et al. Discovery of thiophene-2-carboxylic acids as potent inhibitors of HCV NS5B polymerase and HCV subgenomic RNA replication. Part 1: sulfonamides. Bioorg Med Chem Lett 2004;14:793–6.
   PubMed Web of Science ®Google Scholar
• Le Pogam S, Kang H, Harris SF, et al. Selection and characterization of replicon variants dually resistant to thumb- and palm-binding nonnucleoside polymerase inhibitors of the hepatitis C virus. J Virol 2006;80:6146–54.
   PubMed Web of Science ®Google Scholar
• Shaw AN, Tedesco R, Bambal R, et al. Substituted benzothiadizine inhibitors of hepatitis C virus polymerase. Bioorg Med Chem Lett 2009;19:4350–3.
   PubMed Web of Science ®Google Scholar
• Dragovich PS, Blazel JK, Ellis DA, et al. Novel HCV NS5B polymerase inhibitors derived from 4-(1′,1′-dioxo-1′,4′-dihydro-1′lambda(6)-benzo[1′,2′,4′]thiadiazin-3′-yl)-5-hydroxy-2H-pyridazin-3-ones. Part 5: exploration of pyridazinones containing 6-amino-substituents. Bioorg Med Chem Lett 2008;18:5635–9.
   PubMed Web of Science ®Google Scholar
• Wang G, Lei H, Wang X, et al. HCV NS5B polymerase inhibitors 2: synthesis and in vitro activity of (1,1-dioxo-2H-[1,2,4]benzothiadiazin-3-yl)azolo[1,5-a]pyridine and azolo[1,5-a]pyrimidine derivatives. Bioorg Med Chem Lett 2009;19:4480–3.
   PubMed Web of Science ®Google Scholar
• de Vicente J, Hendricks RT, Smith DB, et al. Non-nucleoside inhibitors of HCV polymerase NS5B. Part 4: structure-based design, synthesis, and biological evaluation of benzo[d]isothiazole-1,1-dioxides. Bioorg Med Chem Lett 2009;19:5652–6.
   PubMed Web of Science ®Google Scholar
• Li LS, Zhou Y, Murphy DE, et al. Novel HCV NS5B polymerase inhibitors derived from 4-(1′,1′-dioxo-1′,4′-dihydro-1′lambda(6)-benzo[1′,2′,4′]thiadiazin-3′-yl)-5-hydroxy-2H-pyridazin-3-ones. Part 3: further optimization of the 2-, 6-, and 7′-substituents and initial pharmacokinetic assessments. Bioorg Med Chem Lett 2008;18:3446–55.
   PubMed Web of Science ®Google Scholar
• Ruebsam F, Webber SE, Tran MT, et al. Pyrrolo[1,2-b]pyridazin-2-ones as potent inhibitors of HCV NS5B polymerase. Bioorg Med Chem Lett 2008;18:3616–21.
   PubMed Web of Science ®Google Scholar
• de Vicente J, Hendricks RT, Smith DB, et al. Non-nucleoside inhibitors of HCV polymerase NS5B. Part 3: synthesis and optimization studies of benzothiazine-substituted tetramic acids. Bioorg Med Chem Lett 2009;19:5648–51.
   PubMed Web of Science ®Google Scholar
• Ellis DA, Blazel JK, Tran CV, et al. 5,5′- and 6,6′-dialkyl-5,6-dihydro-1H-pyridin-2-ones as potent inhibitors of HCV NS5B polymerase. Bioorg Med Chem Lett 2009;19:6047–52.
   PubMed Web of Science ®Google Scholar
• Kim SH, Tran MT, Ruebsam F, et al. Structure-based design, synthesis, and biological evaluation of 1,1-dioxoisothiazole and benzo[b]thiophene-1,1-dioxide derivatives as novel inhibitors of hepatitis C virus NS5B polymerase. Bioorg Med Chem Lett 2008;18:4181–5.
   PubMed Web of Science ®Google Scholar
• de Vicente J, Hendricks RT, Smith DB, et al. Non-nucleoside inhibitors of HCV polymerase NS5B. Part 2: synthesis and structure-activity relationships of benzothiazine-substituted quinolinediones. Bioorg Med Chem Lett 2009;19:3642–6.
   PubMed Web of Science ®Google Scholar
• Zhou Y, Webber SE, Murphy DE, et al. Novel HCV NS5B polymerase inhibitors derived from 4-(1′,1′-dioxo-1′,4′-dihydro-1′lambda6-benzo[1′,2′,4′]thiadiazin-3′-yl)-5-hydroxy -2H-pyridazin-3-ones. Part 1: exploration of 7′-substitution of benzothiadiazine. Bioorg Med Chem Lett 2008;18:1413–18.
   PubMed Web of Science ®Google Scholar
• Ruebsam F, Sun Z, Ayida BK, et al. Hexahydro-pyrrolo- and hexahydro-1H-pyrido[1,2-b]pyridazin-2-ones as potent inhibitors of HCV NS5B polymerase. Bioorg Med Chem Lett 2008;18:5002–5.
   PubMed Web of Science ®Google Scholar
• Ellis DA, Blazel JK, Webber SE, et al. 4-(1,1-Dioxo-1,4-dihydro-1lambda6-benzo[1,4]thiazin-3-yl)-5-hydroxy-2H-pyridazin-3-ones as potent inhibitors of HCV NS5B polymerase. Bioorg Med Chem Lett 2008;18:4628–32.
   PubMed Web of Science ®Google Scholar
• Nittoli T, Curran K, Insaf S, et al. Identification of anthranilic acid derivatives as a novel class of allosteric inhibitors of hepatitis C NS5B polymerase. J Med Chem 2007;50:2108–16.
   PubMed Web of Science ®Google Scholar
• Antonysamy SS, Aubol B, Blaney J, et al. Fragment-based discovery of hepatitis C virus NS5b RNA polymerase inhibitors. Bioorg Med Chem Lett 2008;18:2990–5.
   PubMed Web of Science ®Google Scholar
• Wang M, Ng KK, Cherney MM, et al. Non-nucleoside analogue inhibitors bind to an allosteric site on HCV NS5B polymerase. Crystal structures and mechanism of inhibition. J Biol Chem 2003;278:9489–95.
   PubMed Web of Science ®Google Scholar
• Yang H, Hendricks RT, Arora N, et al. Cyclic amide bioisosterism: strategic application to the design and synthesis of HCV NS5B polymerase inhibitors. Bioorg Med Chem Lett 2010;20:4614–19.
   PubMed Web of Science ®Google Scholar
• Kumar DV, Rai R, Brameld KA, et al. Quinolones as HCV NS5B polymerase inhibitors. Bioorg Med Chem Lett 2011;21:82–7.
   PubMed Web of Science ®Google Scholar
• Schoenfeld RC, Bourdet DL, Brameld KA, et al. Discovery of a novel series of potent non-nucleoside inhibitors of hepatitis C virus NS5B. J Med Chem 2013;56:8163–82.
   PubMed Web of Science ®Google Scholar
• Pierra Rouviere C, Amador A, Badaroux E, et al. Synthesis of potent and broad genotypically active NS5B HCV non-nucleoside inhibitors binding to the thumb domain allosteric site 2 of the viral polymerase. Bioorg Med Chem Lett 2016;26:4536–41.
   PubMed Web of Science ®Google Scholar
• Stammers TA, Coulombe R, Duplessis M, et al. Anthranilic acid-based Thumb Pocket 2 HCV NS5B polymerase inhibitors with sub-micromolar potency in the cell-based replicon assay. Bioorg Med Chem Lett 2013;23:6879–85.
   PubMed Web of Science ®Google Scholar
• Beaulieu PL, Coulombe R, Duan J, et al. Structure-based design of novel HCV NS5B thumb pocket 2 allosteric inhibitors with submicromolar gt1 replicon potency: discovery of a quinazolinone chemotype. Bioorg Med Chem Lett 2013;23:4132–40.
   PubMed Web of Science ®Google Scholar